{"response": "{\n    \"dataset_reused\": false,\n    \"usage_type\": \"methodological_reference\",\n    \"confidence\": 0.95,\n    \"research_question\": \"How can the type II bacterial CRISPR system be engineered to function with custom guide RNA in human cells?\",\n    \"application_domain\": \"Genome engineering\",\n    \"methodology\": \"CRISPR/Cas9 genome editing\",\n    \"sample_info\": \"293T cells, K562 cells, and induced pluripotent stem cells\",\n    \"key_findings\": [\n        \"Targeting rates of 10 to 25% in 293T cells, 13 to 8% in K562 cells, and 2 to 4% in induced pluripotent stem cells were obtained for the endogenous AAVS1 locus.\",\n        \"The editing process is sequence-specific and relies on CRISPR components.\",\n        \"Simultaneous introduction of multiple gRNAs can effect multiplex editing of target loci.\",\n        \"A genome-wide resource of ~190 K unique gRNAs targeting ~40.5% of human exons was computed.\"\n    ],\n    \"clinical_relevance\": \"medium\",\n    \"clinical_details\": null,\n    \"novel_biomarkers\": [],\n    \"validation_status\": \"none\",\n    \"reasoning\": \"The citing paper does not explicitly state that it downloaded, analyzed, or reanalyzed data from the original dataset paper. Instead, it references the CRISPR/Cas9 technology and methodology developed in the original paper as a foundation for its own research into engineering the system for use in human cells with custom guide RNA. The focus is on applying and extending the CRISPR/Cas9 technology rather than analyzing data from the original study.\"\n}", "model": "gpt-4-turbo-preview"}
